Neoplasms

All Conditions

Heart and Blood Diseases

Digestive System Diseases

Symptoms and General Pathology

Rare Diseases

Carcinoma

Hypertension

Carcinoma, Hepatocellular

Hypertension, Portal

Hemorrhage

Varicose Veins

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Acute Graft Versus Host Disease

Anti-Arrhythmia Agents

Antihypertensive Agents

Vasodilator Agents

All Drugs and Chemicals

Propranolol

Adrenergic beta-Antagonists

Adrenergic Agents

Adrenergic Antagonists

Neurotransmitter Agents

Endoscopic treatment alone is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.

endoscopic variceal ligation (EVL) or Gastric Variceal Sclerotherapy (GVS)

Endoscopic treatment alone versus combined propranolol is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.

Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period

propranolol

Ming Chih Hou, MD

Patients with hepatocellular carcinoma and esophageal varices bleeding were randomized to undergo endoscopic ligation alone (group A) and additive propranolol treatment (group B) after stabilization of their first acute bleeding.

Esophageal variceal bleeding is characteristic of high rebleeding rate and mortality. Thanks to the recent advance of treatment for variceal bleeding such as non-selective beta blocker (NSBB) added to endoscopic ligation further reduce rebleeding in cirrhotic patients, the rebleeding rate and mortality has a marked reduction. However, hepatocellular carcinoma (HCC) is a distinct group characteristic of very poor prognosis in patients with portal hypertension when compared to those of liver cirrhosis only. Therefore, the investigators design a study to randomize patients with HCC and acute variceal bleeding to endoscopic treatment alone and combination with endoscopic treatment and NSBB. This is the two years study.

A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC)

Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma

Taipei Veterans General Hospital, Taiwan

Thrombosis

Venous Thrombosis

Embolism

Embolism and Thrombosis

Vascular Diseases

Channel Blockers

Bone Density Conservation Agents

Carvedilol

Antioxidants

Protective Agents

Calcium

Calcium Channel Blockers

Calcium, Dietary

Hormones

Adrenergic alpha-1 Receptor Antagonists

Adrenergic alpha-Antagonists

Endoscopic Variceal Ligation every 3 weeks till eradication

Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD

Endoscopic Variceal Ligation every 3 weeks till eradication.

Endoscopic Variceal Ligation

Dr Shakti P Choudhury, MD

Every patient with HCC (Hepato-Cellular Carcinoma) with main portal vein thrombosis will be screened for presence of large esophageal varices and will be randomized between non-selective beta blocker versus primary endoscopic variceal ligation. They will be followed to assess the rate of reduction of index bleed rate as well as survival difference between the groups.

Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.

A Prospective Randomized Controlled Trial Comparing Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis

Institute of Liver and Biliary Sciences, India

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC)	NCT01451658	Gastroesophagea... Hepatocellular ...	propranolol	18 Years - 80 Years	Taipei Veterans General Hospital, Taiwan
A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC)	NCT01451658	Gastroesophagea... Hepatocellular ...	propranolol	18 Years - 80 Years	Taipei Veterans General Hospital, Taiwan
Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.	NCT01659346	Hepatocellular ...	Endoscopic Vari... Carvedilol	18 Years - 65 Years	Institute of Liver and Biliary Sciences, India
Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.	NCT01659346	Hepatocellular ...	Endoscopic Vari... Carvedilol	18 Years - 65 Years	Institute of Liver and Biliary Sciences, India
A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC)	NCT01451658	Gastroesophagea... Hepatocellular ...	propranolol	18 Years - 80 Years	Taipei Veterans General Hospital, Taiwan

Spots Global Cancer Trial Database for endoscopic variceal ligation